Kurs & Likviditet
Kalender
2024-11-12 | Kvartalsrapport 2024-Q3 |
2024-08-13 | Kvartalsrapport 2024-Q2 |
2024-05-15 | Ordinarie utdelning MOB 0.00 SEK |
2024-05-14 | Årsstämma 2024 |
2024-05-07 | Kvartalsrapport 2024-Q1 |
2024-02-13 | Bokslutskommuniké 2023 |
2023-11-07 | Kvartalsrapport 2023-Q3 |
2023-10-09 | Extra Bolagsstämma 2023 |
2023-08-03 | Kvartalsrapport 2023-Q2 |
2023-05-24 | Split MOB 10:1 |
2023-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2023-05-16 | Årsstämma 2023 |
2023-05-09 | Kvartalsrapport 2023-Q1 |
2023-02-07 | Bokslutskommuniké 2022 |
2022-11-08 | Kvartalsrapport 2022-Q3 |
2022-08-09 | Kvartalsrapport 2022-Q2 |
2022-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2022-05-16 | Årsstämma 2022 |
2022-05-10 | Kvartalsrapport 2022-Q1 |
2022-05-03 | Extra Bolagsstämma 2022 |
2022-02-08 | Bokslutskommuniké 2021 |
2021-11-09 | Kvartalsrapport 2021-Q3 |
2021-08-10 | Kvartalsrapport 2021-Q2 |
2021-05-11 | Kvartalsrapport 2021-Q1 |
2021-03-31 | Ordinarie utdelning MOB 0.00 SEK |
2021-03-30 | Årsstämma 2021 |
2021-02-09 | Bokslutskommuniké 2020 |
2020-12-01 | Extra Bolagsstämma 2020 |
2020-05-12 | Kvartalsrapport 2020-Q3 |
2020-02-11 | Kvartalsrapport 2020-Q2 |
2019-11-19 | Kvartalsrapport 2020-Q1 |
2019-11-04 | Inlösen MOB 46.5 |
2019-10-31 | Ordinarie utdelning MOB 0.00 SEK |
2019-10-30 | Årsstämma 2020 |
2019-08-29 | Bokslutskommuniké 2019 |
2019-05-16 | Ordinarie utdelning MOB 0.00 SEK |
2019-05-15 | Årsstämma 2019 |
2019-05-14 | Kvartalsrapport 2019-Q1 |
2019-03-15 | Extra Bolagsstämma 2019 |
2019-02-12 | Bokslutskommuniké 2018 |
2018-11-06 | Kvartalsrapport 2018-Q3 |
2018-08-07 | Kvartalsrapport 2018-Q2 |
2018-05-16 | Ordinarie utdelning MOB 0.00 SEK |
2018-05-15 | Årsstämma 2018 |
2018-05-08 | Kvartalsrapport 2018-Q1 |
2018-02-13 | Bokslutskommuniké 2017 |
2017-11-13 | Kvartalsrapport 2017-Q3 |
2017-08-08 | Kvartalsrapport 2017-Q2 |
2017-05-17 | Ordinarie utdelning MOB 0.00 SEK |
2017-05-16 | Årsstämma 2017 |
2017-05-09 | Kvartalsrapport 2017-Q1 |
2017-02-14 | Bokslutskommuniké 2016 |
2016-11-08 | Kvartalsrapport 2016-Q3 |
2016-08-09 | Kvartalsrapport 2016-Q2 |
2016-05-19 | Ordinarie utdelning MOB 0.00 SEK |
2016-05-18 | Årsstämma 2016 |
2016-05-10 | Kvartalsrapport 2016-Q1 |
2016-02-17 | Bokslutskommuniké 2015 |
2015-11-10 | Kvartalsrapport 2015-Q3 |
2015-08-11 | Kvartalsrapport 2015-Q2 |
2015-05-12 | Ordinarie utdelning MOB 0.00 SEK |
2015-05-11 | Årsstämma 2015 |
2015-05-11 | Bokslutskommuniké 2014 |
2015-05-11 | Kvartalsrapport 2015-Q1 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-11-14 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Kvartalsrapport 2014-Q2 |
2014-05-14 | Ordinarie utdelning MOB 0.00 SEK |
2014-05-13 | Årsstämma 2014 |
2014-05-13 | Kvartalsrapport 2014-Q1 |
2014-02-20 | Bokslutskommuniké 2013 |
2013-11-05 | Kvartalsrapport 2013-Q3 |
2013-08-06 | Kvartalsrapport 2013-Q2 |
2013-05-21 | Kvartalsrapport 2013-Q1 |
2013-05-21 | Analytiker möte 2013 |
2013-04-24 | Ordinarie utdelning MOB 0.00 SEK |
2013-04-23 | Årsstämma 2013 |
2013-03-13 | 15-7 2013 |
2013-02-05 | Bokslutskommuniké 2012 |
2012-11-19 | Extra Bolagsstämma 2012 |
2012-10-25 | Kvartalsrapport 2012-Q3 |
2012-09-20 | Kapitalmarknadsdag 2012 |
2012-08-28 | Kvartalsrapport 2012-Q2 |
2012-06-11 | 15-7 2012 |
2012-04-24 | Ordinarie utdelning MOB 0.00 SEK |
2012-04-23 | Årsstämma 2012 |
2012-04-23 | Kvartalsrapport 2012-Q1 |
2012-02-09 | Bokslutskommuniké 2011 |
2011-11-29 | 15-7 2011 |
2011-10-28 | Kvartalsrapport 2011-Q3 |
2011-08-12 | Kvartalsrapport 2011-Q2 |
2011-04-18 | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
STOCKHOLM, February 4th, 2019. On February 12th, 2019, it was announced that Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has entered into agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest its entire commercial operations. Further information regarding the proposed divestment of the OTC-business has today been published and is available in the form of an information document.
The information document describes the proposed transaction as well as the Company's continued operations following a divestment of the OTC-business. The information document contains among other things financial pro forma information in the form of income statement and balance sheet for 2018, the background and reasons for the proposed divestment and detailed information regarding the different elements of the transaction.
The information document is only available in Swedish. However, the pro forma information is available in English in the form of a translation. The information document and the translation are available on the Company's website, http://www.mobergpharma.com/investors/calendarpresentations.
The published information document is to be used for information purposes only and as a basis for assessing the consequences of the proposed divestment of the OTC-business of Moberg Pharma and actions related thereto, which are described in the information document. The information document does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares or other securities in Moberg Pharma. The published information document has not been approved by any regulatory authority and is not a prospectus.
Peter Wolpert, CEO, phone: Sweden: +46 707 35 7135, US: +1 908 432 2203,
Anna Ljung, CFO, phone: +46 707 66 6030, e-mail:
About this information
The information was submitted for publication, through the contact persons set out above, at 8.30 a.m. (CET) on March 4th, 2019.